Conclusion Of A Non-exclusive Discount Agreement According To § 130a (8) Sgb V For The Active Ingredient Perindopril + Amlodipine, Atc C09bb04, For The Period 1.4.2021-31.3.2023
Conclusion Of A Non-exclusive Discount Agreement According To § 130a (8) Sgb V For The Active Ingredient Latanoprost (only Dosage Forms As Single Doses, For The Period 1.6.2021-31.5.2023